Tabula Rasa Healthcare, Inc. (TRHC) Reaches $37.10 After 6.00% Down Move; Crosslink Capital Has Lowered Lam Research (LRCX) Position

February 15, 2018 - By Peter Erickson

Crosslink Capital Inc decreased Lam Research (LRCX) stake by 36.32% reported in 2017Q3 SEC filing. Crosslink Capital Inc sold 49,670 shares as Lam Research (LRCX)’s stock rose 32.64%. The Crosslink Capital Inc holds 87,093 shares with $16.12M value, down from 136,763 last quarter. Lam Research now has $29.91 billion valuation. The stock increased 0.29% or $0.53 during the last trading session, reaching $183.54. About 2.96 million shares traded. Lam Research Corporation (NASDAQ:LRCX) has risen 107.86% since February 15, 2017 and is uptrending. It has outperformed by 91.16% the S&P500.

The stock of Tabula Rasa Healthcare, Inc. (NASDAQ:TRHC) is a huge mover today! The stock decreased 2.42% or $0.92 during the last trading session, reaching $37.1. About 164,049 shares traded. Tabula Rasa Healthcare, Inc. (NASDAQ:TRHC) has 0.00% since February 15, 2017 and is . It has underperformed by 16.70% the S&P500.The move comes after 8 months negative chart setup for the $711.65M company. It was reported on Feb, 15 by We have $34.87 PT which if reached, will make NASDAQ:TRHC worth $42.70 million less.

Since September 11, 2017, it had 0 insider buys, and 11 insider sales for $12.77 million activity. Shares for $1.49M were sold by ARCHER TIMOTHY. NEWBERRY STEPHEN G sold $146,318 worth of stock or 750 shares. Varadarajan Seshasayee sold $5.47M worth of stock.

Investors sentiment increased to 1.02 in Q3 2017. Its up 0.04, from 0.98 in 2017Q2. It is positive, as 51 investors sold LRCX shares while 238 reduced holdings. 87 funds opened positions while 207 raised stakes. 146.35 million shares or 1.92% less from 149.22 million shares in 2017Q2 were reported. Strategy Asset Managers Ltd Limited Liability Company stated it has 0.89% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). Bankshares Of Montreal Can owns 0.26% invested in Lam Research Corporation (NASDAQ:LRCX) for 1.55M shares. Perkins Coie Tru, a Washington-based fund reported 433 shares. Commonwealth Equity Svcs Inc accumulated 17,798 shares or 0.02% of the stock. Calamos Wealth Mgmt Ltd Liability Corporation stated it has 0.83% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). Hartford Investment Comm has 0.12% invested in Lam Research Corporation (NASDAQ:LRCX) for 35,012 shares. Renaissance Techs Llc has 0.15% invested in Lam Research Corporation (NASDAQ:LRCX). Rainier Ltd Liability has invested 0.95% in Lam Research Corporation (NASDAQ:LRCX). Old Mutual Customised Solutions (Proprietary) Limited stated it has 0.13% of its portfolio in Lam Research Corporation (NASDAQ:LRCX). British Columbia Investment invested in 144,227 shares. Pictet Cie (Europe) Sa has 6,342 shares. Stratos Wealth Limited reported 3,379 shares or 0.03% of all its holdings. Odey Asset Mgmt Grp holds 51,398 shares. Virginia Retirement Et Al has invested 0.43% in Lam Research Corporation (NASDAQ:LRCX). Advantage invested 0.01% in Lam Research Corporation (NASDAQ:LRCX).

Among 25 analysts covering Lam Research Corporation (NASDAQ:LRCX), 24 have Buy rating, 0 Sell and 1 Hold. Therefore 96% are positive. Lam Research Corporation had 79 analyst reports since September 17, 2015 according to SRatingsIntel. Needham maintained Lam Research Corporation (NASDAQ:LRCX) on Friday, June 16 with “Buy” rating. The stock has “Buy” rating by Credit Suisse on Wednesday, October 18. The rating was maintained by Needham on Thursday, July 27 with “Buy”. Citigroup maintained it with “Buy” rating and $102 target in Friday, August 12 report. Morgan Stanley maintained Lam Research Corporation (NASDAQ:LRCX) rating on Thursday, January 25. Morgan Stanley has “Overweight” rating and $238 target. The rating was downgraded by Pacific Crest on Wednesday, October 12 to “Sector Weight”. On Monday, September 21 the stock rating was maintained by Susquehanna with “Neutral”. KeyBanc Capital Markets maintained the shares of LRCX in report on Wednesday, January 24 with “Buy” rating. The company was upgraded on Monday, December 19 by Goldman Sachs. The company was downgraded on Thursday, August 11 by Nomura.

Analysts await Tabula Rasa Healthcare, Inc. (NASDAQ:TRHC) to report earnings on March, 12. They expect $0.12 earnings per share, up 300.00% or $0.18 from last year’s $-0.06 per share. TRHC’s profit will be $2.30 million for 77.29 P/E if the $0.12 EPS becomes a reality. After $0.02 actual earnings per share reported by Tabula Rasa Healthcare, Inc. for the previous quarter, Wall Street now forecasts 500.00% EPS growth.

Tabula Rasa HealthCare, Inc. provides patient-specific, data-driven technology and solutions that enable healthcare organizations to optimize medication regimens to enhance patient outcomes, reduce hospitalizations, lower healthcare costs, and manage risk. The company has market cap of $711.65 million. The Company’s cloud software applications include EireneRx, which is used by at-risk healthcare organizations to access its patients' medication-related information; MedWise Advisor that allows for components of EireneRx to be used independently and by a broader healthcare audience; and NiaRx, an educational software platform used in the pharmacy educational community. It currently has negative earnings. The firm offers its technology-enabled services and products for medication risk management and risk adjustment.

Among 3 analysts covering Tabula Rasa HealthCare (NASDAQ:TRHC), 3 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Tabula Rasa HealthCare had 3 analyst reports since October 24, 2016 according to SRatingsIntel. The stock of Tabula Rasa Healthcare, Inc. (NASDAQ:TRHC) has “Buy” rating given on Monday, October 24 by UBS. The stock of Tabula Rasa Healthcare, Inc. (NASDAQ:TRHC) earned “Outperform” rating by Wells Fargo on Monday, October 24. The rating was initiated by Piper Jaffray with “Overweight” on Monday, October 24.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:

Recent Posts